115178-28-4

Basic information

• Product Name: (8alpha,10xi)-8-(1H-imidazol-1-ylmethyl)-6-methylergoline
• CAS NO: 115178-28-4
• Molecular Formula: C₁₉H₂₂N₄
• Molecular Weight: 306.4048
• Mol File: 115178-28-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 560.8°C at 760 mmHg
• Flash Point: 293°C
• Density: 1.35g/cm³
• Vapor Pressure: 1.31E-12mmHg at 25°C
• Refractive Index: 1.74
• CAS DataBase Reference: (8alpha,10xi)-8-(1H-imidazol-1-ylmethyl)-6-methylergoline(CAS DataBase Reference)
• NIST Chemistry Reference: (8alpha,10xi)-8-(1H-imidazol-1-ylmethyl)-6-methylergoline(115178-28-4)
• EPA Substance Registry System: (8alpha,10xi)-8-(1H-imidazol-1-ylmethyl)-6-methylergoline(115178-28-4)

Safety Data

• Hazardous Substances Data: 115178-28-4(Hazardous Substances Data)

Usage

General Description

The chemical "(8alpha,10xi)-8-(1H-imidazol-1-ylmethyl)-6-methylergoline" is a compound belonging to the ergoline class of alkaloids. It has a molecular structure consisting of an ergoline ring system with a side chain attached at the eighth carbon and a methyl group at the sixth carbon. The side chain contains an imidazole group, which gives the chemical its unique properties. (8alpha,10xi)-8-(1H-imidazol-1-ylmethyl)-6-methylergoline is known to have potential pharmacological activities and is being studied for its potential use in the treatment of various medical conditions. Its specific biological and pharmacological effects are still being investigated, and further research is required to fully understand its potential applications.

Upstream product

• 288-32-4 1H-imidazole 
• 96737-35-8 6-methyl-8α-(toluene-4-sulfonyloxymethyl)-ergoline 
• 3006-19-7 9,10-dihydrolysergic acid methyl ester 
• 5878-43-3 9,10-dihydrolysergic acid 
• 18051-16-6 9,10-dihydrolysergol 
• 58752-31-1 6-methyl-8β-tosyloxymethyl-ergoline 

Relevant articles and documents

Synthesis and structure-activity relationships of new (5R,8S,10R)-ergoline derivatives with antihypertensive of dopaminergic activity

A series of new (5R,8S,10R)-ergoline derivatives was synthesized, and their antihypertensive and dopaminergic activities were evaluated in conscious spontaneously hypertensive rats and in rats with unilateral 6-hydroxydopamine-induced lesions of the substantia nigra, respectively. (5R,8S,10R)-6-Methyl-8-ergolinemethanols, prepared from the corresponding ergolinecarboxylates, were converted to the tosylates, which were treated with various five-membered heterocycles containing nitrogen atoms to afford the new ergolines. (5R,8S,10R)-8-(1-Imidazolylmethyl)-6-methylergoline (5a, BAM-2101) and (5R,8S,10R)-2-bromo-6-methyl-8-(1,2,4-triazol-1-ylmethyl)ergoline (7c, BAM-2202) exhibited potent antihypertensive activities. The maximum falls of systolic blood presure after oral administration of 5a and 7c at 3 mg/kg were 95 and 132 mmHg, respectively, while those of cianergoline, bromocriptine mesylate, hydralazine, and nifedipine at the same dose were 40, 37, 47, and 49 mmHg, respectively. The durations of significant antihypertensive effects of these compounds except nifedipine were more than 7 h. None of the ergolines exhibited potent dopaminergic activity. Structure-activity relationships are discussed.

Ergoline derivatives and acid addition salts thereof

Novel ergoline derivatives and acid addition salts thereof are disclosed. These ergoline derivatives possess excellent anti-hypertensive activity, vasodilating activity, anti-ulcer activity, gastric secretion inhibitory activity, brain metabolism improving activity, anti-depressive activity and dopamine-like activity, and, therefore, are useful for prevention and treatment of various diseases such as hypertension, a wide variety of vein disorders, peptic ulcer, brain absormality, depression, Parkinson's disease, high prolactin blood disease, etc.